Prot #20210004: A Randomized, Open-Label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-Based First-Line Chemotherapy (DeLLphi-304)

Project: Research project

Project Details

StatusActive
Effective start/end date2/29/242/28/27

Funding

  • Amgen, Inc. (Prot #20210004)